Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course

被引:65
|
作者
Miller, Elzbieta [1 ,2 ]
Walczak, Anna [3 ]
Majsterek, Ireneusz [3 ]
Kedziora, Jozef [4 ]
机构
[1] Med Univ Lodz, Dept Phys Med, PL-94124 Lodz, Poland
[2] III Gen Hosp Lodz, Neurorehabil Ward, Lodz, Poland
[3] Med Univ Lodz, Dept Chem & Clin Biochem, PL-94124 Lodz, Poland
[4] Nicholas Copernicus Univ, Chair & Dept Biochem, Coll Med Bydgoszcz, Torun, Poland
关键词
Melatonin; Oxidative stress; Multiple sclerosis; DISABILITY STATUS; AUTOXIDATION; STROKE; BRAIN; MICE;
D O I
10.1016/j.jneuroim.2013.02.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Oxidative stress plays a major role in multiple sclerosis (MS). melatonin is a potent neuroprotectant. The aims of this study were to determine the actions of melatonin in the reduction of oxidative stress in MS. Therefore, we estimated lipid peroxidation and activities of main antioxidative enzymes in the red blood cells (RBCs) from selective group of MS patients only with secondary progressive (SPMS) clinical form and verified results with functional state. The sixteen (n = 16) SPMS patients were supplemented with melatonin (10 mg daily/30 days). Age matched healthy subjects were used as a control (n = 13). We determined the level of lipid peroxidation by malondialdehyde (MDA) and activities of main antioxidative enzymes: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxide (GPx) in RBCs of SPMS patients. Melatonin caused statistically significant increase of SOD, GPx (p < 0.0001 and p = 0.004065, respectively) and decrease of MDA in erythrocytes of SPMS patients (p = 0.00019). Correlation analysis of Spearman showed positive correlation between SOD and (expanded disability status scale) EDSS scale both before (r = 0.64, p = 0.00756) and after (r = 0.634, p = 0.00834) melatonin treatment. These results demonstrate that supplementation with melatonin SPMS patients should be taken into account, especially in progressive form of MS. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 50 条
  • [21] Objective classification of multiple sclerosis disease course results in frequent reclassification to secondary progressive multiple sclerosis
    Hillert, Jan
    Forsberg, Lars
    Manouchehrinia, Ali
    Ramanujam, Ryan
    Spelman, Timothy
    Klyve, Pernilla
    Drahota, Jiri
    Horakova, Dana
    Joensen, Hanna
    Magyari, Melinda
    Ellenberger, David
    Stahmann, Alexander
    Van der Walt, Anneke
    Rodgers, Jeff
    Witts, James A.
    Middleton, Rod
    Nicholas, Richard
    Bezlyak, Vladimir
    Adlard, Nicholas
    Hach, Thomas
    Lines, Carol
    Glaser, Anna
    NEUROLOGY, 2021, 96 (15)
  • [22] Oral Masitinib in Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis
    Vermersch, Patrick
    Benrabah, Rabah
    Schmidt, Nicolas
    Zephir, Helene
    Chen, Pierre
    Vongsouthi, Cyrille
    Moussy, Alain
    Hermine, Olivier
    NEUROLOGY, 2009, 72 (11) : A313 - A314
  • [23] Longitudinal changes of cerebral glutathione levels in patients with secondary progressive multiple sclerosis may reflect the clinical course of disease progression
    Choi, I. -Y.
    Lee, P.
    Denney, D.
    Lynch, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 380 - 380
  • [24] Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis
    Choi, In-Young
    Lee, Phil
    Hughes, Abbey J.
    Denney, Douglas R.
    Lynch, Sharon G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (07) : 956 - 962
  • [25] Meningeal inflammation is widespread and linked to cortical pathology and an accelerated clinical course in secondary progressive multiple sclerosis
    Howell, O.
    Reeves, C.
    Nicholas, R.
    Carassiti, D.
    Roncaroli, F.
    Magliozzi, R.
    Aloisi, F.
    Gveric, D.
    Reynolds, R.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S39 - S39
  • [26] Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis
    McAdams, Matthew
    Stankiewicz, James M.
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
  • [27] Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools
    Klinsing, Svenja
    Yalachkov, Yavor
    Foerch, Christian
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1100 - 1105
  • [28] Clinical and demographic aspects of secondary progressive multiple sclerosis in Argentina
    Miguez, Jimena
    Serena, Marina Alonso
    Pappolla, Agustin
    Patrucco, Liliana
    Cristiano, Edgardo
    Vrech, Carlos
    Rojas, Juan, I
    Alonso, Ricardo
    Cohen, Leila
    Garcea, Orlando
    Pita, Cecilia
    Silva, Berenice A.
    Gaitan, Maria, I
    Marrodan, Mariano
    Negrotto, Laura
    Ysrraelit, Maria C.
    Luetic, Geraldine
    Deri, Norma
    Caride, Alejandro
    Carnero Contentti, Edgar
    Lopez, Pablo A.
    Pablo Pettinicchi, Juan
    Carra, Adriana
    Curbelo, Celeste
    Martinez, Alejandra D.
    Steinberg, Judith D.
    Balbuena, Maria E.
    Tkachuk, Veronica
    Burgos, Marcos
    Knorre, Eduardo
    Leguizamon, Felisa
    Liwacki, Susana del, V
    Piedrabuena, Raul
    Barboza, Andres G.
    Nofal, Pedro
    Volman, Gabriel
    Alvez Pinheiro, Amelia
    Hryb, Javier
    Tavolini, Dario
    Blaya, Patricio A.
    Silva, Emanuel
    Blanche, Jorge
    Tizio, Santiago
    Caceres, Fernando
    Laura Saladino, Maria
    Zanga, Gisela
    Fracaro, Maria E.
    Sgrilli, Gustavo
    Pagani Cassara, Fatima
    Vazquez, Guido
    MEDICINA-BUENOS AIRES, 2020, 80 (06) : 606 - 610
  • [29] Oxidative Stress Imbalance in Multiple Sclerosis Patients
    Gironi, Maira
    Vaghi, Matilde
    Mariani, Enrica
    Cursano, Cristina
    di Stolfo, Valentina
    Tortorella, Paola
    Nemni, Raffaello
    Saresella, Marina
    Rovaris, Marco
    NEUROLOGY, 2012, 78
  • [30] Multiple sclerosis and oxidative stress-a clinical perspective
    Kostic, M. S.
    Rajkovic, J. S.
    Floranovic, M. S. Potic
    Dimov, I. D.
    Pavlovic, D. D.
    NEUROCHEMICAL JOURNAL, 2013, 7 (01) : 76 - 86